1

Heart Inflammation Linked to COVID Vaccines in Study of U.S. Military, Department of Defense Confirms

By Megan Redshaw | The Defender

new study of U.S. service members found higher than expected rates of heart inflammation following receipt of a COVID vaccine. It’s a finding Defense Department researchers say should call attention to the condition, known as myocarditis, as a potential side effect of vaccinations.

In a study published June 29 in JAMA Cardiology, U.S. military physicians described 23 cases of myocarditis in previously healthy males who developed the condition within four days of receiving a COVID vaccine.

total of 23 male patients (22 currently serving in the military and 1 retiree) with a median age range of 25 years were evaluated between January and April 2021 for acute-onset chest pain following vaccination with an mRNA COVID vaccine.

All military members were previously healthy with a high level of fitness. They were physically fit by military standards and lacked any known history of cardiac disease, significant cardiac risk factors, or exposure to cardiotoxic agents.

Seven military members received Pfizer’s COVID vaccine and 16 received the Moderna vaccine. Each patient had a final diagnosis of myocarditis without infectious, ischemic, or autoimmune etiologies identified. Diagnoses were reviewed and met the U.S. Centers for Disease Control and Prevention’s (CDC) case definition criteria for probable myocarditis.

All patients presented with acute chest pain and significantly elevated cardiac troponin levels (10-fold to 400-fold the upper limits of their respective reference ranges) with symptom onset within 12 to 96 hours following COVID vaccination.

According to the study, physicians expected to find eight or fewer cases of myocarditis among the 436,000 male military members who received two mRNA doses. But 20 military members developed inflammation after their second dose, including 14 after the Moderna shot and six after the Pfizer shot. Three developed myocarditis after their first vaccine.

Cardiac symptoms resolved within a week of onset for 16 patients, but seven continued to have chest pain at the time of publication.

The researchers stated that while the true incidence of myocarditis is unknown at this time, the presentation pattern and clinical course suggest an association with an inflammatory response to vaccination.

The team concluded that increased attention to myocarditis as a potential adverse event following vaccination is warranted.

A new study supports the link between mRNA COVID vaccines and heart inflammation

A separate study published in JAMA Cardiology on June 29 investigated seven cases of acute myocarditis. Four cases occurred within five days of COVID vaccination between Feb. 1 and April 30.

All four patients had received the second dose of an mRNA vaccine and presented with severe chest pain, had biomarker evidence of myocardial injury, were hospitalized, and had test results consistent with myocarditis.

“It is possible that these four cases of acute myocarditis represent a rare, potential adverse event linked to mRNA COVID-19 vaccination,” researchers wrote. “The findings from the present report raise the possibility of an association between mRNA COVID-19 vaccination and acute myocarditis.”

An association between COVID vaccines and myocarditis was first reported in Israel with a case study in February involving a 19-year-old male.

On April 26, details leaked from an Israeli Health Ministry report raising concerns among experts about a possible link between the Pfizer-BioNTech COVID vaccine and myocarditis.

preliminary report by an Israeli committee tasked with monitoring vaccine side effects found 62 cases of myocarditis, including two deaths, in people who received the Pfizer vaccine. Fifty-six cases occurred after the second dose of the vaccine, and 55 cases occurred in men — most between the ages of 18 and 30.

The two patients who died were reportedly healthy until receiving the vaccine and had no pre-existing conditions.

On April 27, Reuters reported the U.S. Department of Defense was investigating 14 cases of heart inflammation among people who were vaccinated through the military’s health services.

On June 2, Israeli health officials confirmed a probable link between Pfizer’s COVID vaccine and dozens of cases of heart inflammation in young men following the second dose.

As The Defender reported June 10, the CDC’s advisory committee acknowledged a higher-than-expected number of cases of heart inflammation among 16- to 24-year-olds who recently received a second dose of the Pfizer and Moderna COVID vaccines.

Based on a May 24 report from the CDC’s Advisory Committee on Immunization Practices (ACIP) COVID-19 Vaccine Safety Technical Work Group (VaST), the CDC on June 1 updated its website with the following language:

“Data from VAERS [Vaccine Adverse Events Reporting System] show that in the 30-day window following dose 2 mRNA COVID-19 vaccination, there was a higher number of observed than expected myocarditis/pericarditis cases in 16–24-year-olds.”

On June 23, the ACIP said there was a “likely association” of “mild” heart inflammation in adolescents and young adults after vaccination with an mRNA COVID vaccine, and a warning statement was warranted.

The safety panel acknowledged more than 1,200 cases of myocarditis or pericarditis in 16- to-24-year-olds who received an mRNA COVID vaccine, mostly occurring in males after the second dose.

As The Defender reported June 28, the U.S. Food and Drug Administration added a warning to Pfizer and Moderna’s fact sheets indicating an increased risk of myocarditis and pericarditis following vaccination.

According to the latest data from VAERS, there were 1,342  cases of myocarditis and pericarditis (heart inflammation) in all age groups reported in the U.S. following COVID vaccination between Dec.14, 2020 and June 18, 2021.

Of the 1,342 cases reported, 835 cases were attributed to Pfizer, 458 cases to Moderna and 45 cases to Johnson & Johnson’s COVID vaccine.




CDC Admits Teens Vaccinated With Pfizer or Moderna at Higher Risk of Heart Inflammation

By  Megan Redshaw | The Defender

As CNN reported Wednesday, the Centers for Disease Control and Prevention’s (CDC) advisory committee now acknowledges a higher-than-expected number of cases of heart inflammation among 16- to 24-year-olds who recently received a second dose of the Pfizer and Moderna COVID vaccines.

Based on a May 24 report from the CDC’s Advisory Committee on Immunization Practices (ACIP) COVID-19 Vaccine Safety Technical Work Group (VaST), the CDC on June 1 updated its website with the following language:

“Data from VAERS [Vaccine Adverse Events Reporting System] show that in the 30-day window following dose 2 mRNA COVID-19 vaccination, there was a higher number of observed than expected myocarditis/pericarditis cases in 16–24-year-olds.”

The updated language differed significantly from the CDC’s statement two weeks earlier, which said rates of myocarditis were not higher among vaccinated people.

On May 17, the ACIP said it was investigating reports of myocarditis and pericarditis occurring after mRNA COVID vaccine — particularly in adolescents and young adults — that seemed to occur more often in males than females, more often following the second dose and typically within four days after vaccination. Most cases appeared to be “mild.”

The CDC’s VaST Work Group originally said its monitoring systems had not found more cases of myocarditis than would be expected in the population, but members of the committee on vaccinations said healthcare providers should be made aware of the reports of the “potential adverse event.”

On May 26, the CDC announced it was investigating 18 reports of heart inflammation in recently vaccinated teens in Connecticut who received a COVID vaccine. All 18 cases resulted in hospitalization.

study published June 4 in the journal Pediatrics reported seven boys between the ages of 14 and 19 were hospitalized for heart inflammation and chest pain within four days of receiving the second dose of Pfizer’s COVID vaccine, The Defender reported. None of the teens were critically ill, but all were hospitalized.

Only one of the seven boys in the Pediatrics report displayed evidence of a possible previous COVID infection, and doctors determined none of them had a rare inflammatory condition linked with COVID or pre-existing conditions.

The study’s authors concluded it is possible myocarditis or pericarditis may be an additional rare adverse event related to systemic reactogenicity, but “No causal relationship between vaccine administration and myocarditis has been established.”

As The Defender reported today, the Oregon Health Authority has confirmed at least 11 cases of myocarditis or pericarditis — inflammation of the sac surrounding the heart — in all age groups following COVID vaccination.

The latest data from the CDC’s Vaccine Adverse Events Reporting System (VAERS) showed 40 cases of heart inflammation in the 12-17 year adolescent age group reported after COVID vaccination — all associated with Pfizer.

On June 2, Israeli health officials found a “probable” link between Pfizer’s COVID vaccine — which the country has relied on almost exclusively in its vaccination drive — and dozens of cases of heart inflammation in young men following the second dose.

After the ministry received reports of heart inflammation, including myocarditis, following the recent COVID vaccination, a panel of experts was appointed to investigate the issue

In a statement, Pfizer said there is still no indication the cases are due to its vaccine. Myocarditis is often caused by viral infections, and COVID infections have been reported to cause the condition, the drugmaker said.

Pfizer’s partner, BioNTech, said more than 300 million doses of the COVID vaccine have been administered globally and the “benefit-risk profile” of the vaccine remains positive.

“A careful assessment of the reports is ongoing and it has not been concluded,” the company said. “Adverse events, including myocarditis and pericarditis, are being regularly and thoroughly reviewed by the companies as well as by regulatory authorities.”